283 related articles for article (PubMed ID: 17668216)
1. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.
Ringe JD; Schacht E
Rheumatol Int; 2007 Dec; 28(2):103-11. PubMed ID: 17668216
[TBL] [Abstract][Full Text] [Related]
2. Potential of alfacalcidol for reducing increased risk of falls and fractures.
Ringe JD; Schacht E
Rheumatol Int; 2009 Aug; 29(10):1177-85. PubMed ID: 19159932
[TBL] [Abstract][Full Text] [Related]
3. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
4. Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs.
Schacht E; Dukas L; Richy F
J Musculoskelet Neuronal Interact; 2007; 7(2):174-84. PubMed ID: 17627088
[TBL] [Abstract][Full Text] [Related]
5. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
6. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.
Ringe JD; Farahmand P; Schacht E
Rheumatol Int; 2013 Mar; 33(3):637-43. PubMed ID: 22527138
[TBL] [Abstract][Full Text] [Related]
7. Overcoming resistance to bisphosphonates through the administration of alfacalcidol: results of a 1-year, open follow-up study.
Gaál J; Bender T; Varga J; Horváth I; Kiss J; Somogyi P; Surányi P
Rheumatol Int; 2009 Nov; 30(1):25-31. PubMed ID: 19308412
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
Schacht E; Richy F; Reginster JY
J Musculoskelet Neuronal Interact; 2005; 5(3):273-84. PubMed ID: 16172518
[TBL] [Abstract][Full Text] [Related]
9. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
10. Potency of a combined alfacalcidol-alendronate therapy to reduce the risk of falls and fractures in elderly patients with glucocorticoid-induced osteoporosis.
Ringe JD; Schacht E; Dukas L; Mazor Z
Arzneimittelforschung; 2011; 61(2):104-11. PubMed ID: 21428245
[TBL] [Abstract][Full Text] [Related]
11. The D-hormone analog alfacalcidol: the pioneer beyond the horizon of osteoporosis treatment.
Orimo H; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():4-10. PubMed ID: 16142845
[TBL] [Abstract][Full Text] [Related]
12. Alfacalcidol versus plain vitamin D in inflammation induced bone loss.
Scharla SH; Schacht E; Lempert UG
J Rheumatol Suppl; 2005 Sep; 76():26-32. PubMed ID: 16142848
[TBL] [Abstract][Full Text] [Related]
13. Treatment of glucocorticoid-induced low bone mineral density in children: a systematic review.
Jayasena A; Atapattu N; Lekamwasam S
Int J Rheum Dis; 2015 Mar; 18(3):287-93. PubMed ID: 25923606
[TBL] [Abstract][Full Text] [Related]
14. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
Rhee Y; Kang M; Min Y; Byun D; Chung Y; Ahn C; Baek K; Mok J; Kim D; Kim D; Kim H; Kim Y; Myoung S; Kim D; Lim SK
Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
[TBL] [Abstract][Full Text] [Related]
15. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol.
Trabulus S; Altiparmak MR; Apaydin S; Serdengecti K; Sariyar M
Transplant Proc; 2008; 40(1):160-6. PubMed ID: 18261575
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
Richy F; Schacht E; Bruyere O; Ethgen O; Gourlay M; Reginster JY
Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
[TBL] [Abstract][Full Text] [Related]
17. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.
Ringe JD; Dorst A; Faber H; Schacht E; Rahlfs VW
Rheumatol Int; 2004 Mar; 24(2):63-70. PubMed ID: 14513268
[TBL] [Abstract][Full Text] [Related]
18. [Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Von Schacht E; Dambacher MA; Ringe JD; Dukas L
MMW Fortschr Med; 2012 Apr; 154 Suppl 1():10-21. PubMed ID: 23427364
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Yonsei Med J; 2009 Aug; 50(4):474-81. PubMed ID: 19718394
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
Guan YT; Cai LL; Ding HX; Chen GD; Hu Y
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
